Starting with the approval of anti-CTLA-4 antibodies for advanced-stage melanoma in 2011, immune checkpoint inhibitors, which now also comprise antibodies against PD-1 and its ligand (PD-L1), have been rapidly approved by the US Food and Drug Administration (FDA) for the treatment of different cancers [51]. This evidence concerns the gene CTLA4 and cancer.